Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 5/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | SCN1A | P35498 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24041385 | 0.83 | CA1 (0.48) | RAB9AMAPTCASP3SENP8SENP7 | |
| SCHEMBL23723371 | 0.83 | KDM4E (0.51) | RAB9AMAPTCASP3SENP8SENP7 | |
| SCHEMBL15959416 | 0.82 | TSHR (0.47) | RAB9AMAPTTDP1NPC1SMN1; SMN2 | |
| SCHEMBL31734109 | 0.81 | TP53 (0.46) | RAB9AMAPTCA1CA2CA9 | |
| SCHEMBL29246257 | 0.81 | CA1 (0.45) | RAB9AMAPTCASP3SENP8SENP7 | |
| SCHEMBL28504064 | 0.81 | MAPT (0.56) | RAB9AMAPTCA1CA2CA12 | |
| SCHEMBL15714872 | 0.80 | LOXL2 (0.47) | RAB9AMAPTCASP3SENP8SENP7 | |
| SCHEMBL17816425 | 0.79 | TSHR (0.45) | RAB9AMAPTTDP1NPC1SMN1; SMN2 | |
| SCHEMBL13942924 | 0.79 | BCHE (0.45) | RAB9AMAPTTDP1NPC1SMN1; SMN2 | |
| SCHEMBL13653950 | 0.79 | NOS3 (0.53) | RAB9AMAPTL3MBTL1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110218220-B | Functionalized metal-organic framework compound, complex formed by functionalized metal-organic framework compound, and preparation method and application of functionalized metal-organic framework compound | 中山大学 | 2021-11-12 | — | — | CN | claimed |
| CN-110218220-A | A kind of functional metal-organic frame compound, its compound formed and its preparation method and application | 中山大学 | 2019-09-10 | — | — | CN | claimed |
| US-12297178-B2 | Triazole derivative and use thereof | GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) | 2025-05-13 | — | — | US | disclosed |
| CN-118406037-B | Triazole derivative and preparation method and application thereof | 四川师范大学 | 2025-02-25 | — | — | CN | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-118406037-A | Triazole derivative and preparation method and application thereof | 四川师范大学 | 2024-07-30 | — | — | CN | disclosed |
| US-20240166611-A1 | TRIAZOLE DERIVATIVE AND USE THEREOF | GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) | 2024-05-23 | — | — | US | disclosed |
| US-11939314-B2 | Quinolin-2-one derivatives | MERCK PATENT GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-01-18 | — | — | US | disclosed |
| CN-114671816-B | Preparation method of axial chiral aryl triazole compound | 浙江大学 | 2023-11-17 | — | — | CN | disclosed |
| WO-2015076845-A1 | VISCOSIFIED TREATMENT FLUIDS COMPRISING POLYOL DERIVATIZED CELLULOSE AND METHODS RELATING THERETO | HALLIBURTON ENERGY SERVICES, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| CN-103502218-A | Compounds and methods for conjugation of biomolecules | LIFE TECHNOLOGIES CORP | 2014-01-08 | — | — | CN | disclosed |
| EP-2655357-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | Merck Serono S.A. (CH) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| CN-101107357-B | Free reactant for nucleic acid-templated synthesis | HARVARD COLLEGE | 2013-01-02 | — | — | CN | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | disclosed |
| US-7504413-B2 | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases | CYTOKINETICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| CN-101107357-A | Free reactant for nucleic acid-templated synthesis | HARVARD COLLEGE (US) | 2008-01-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | KIF5B, KIF2C, PLK1 | RAB9A 1213/4885MAPT 294/4885CASP3 2838/4885 |
| US-11939314-B2 | Quinolin-2-one derivatives | KIT, CDK2, CDK1 | RAB9A 1889/4885MAPT 4646/4885CASP3 295/4885 |
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | RAB9A 1354/4885MAPT 1670/4885CASP3 2162/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | RAB9A 3390/4885MAPT 2934/4885CASP3 3335/4885 |
| US-12297178-B2 | Triazole derivative and use thereof | FABP4, LIPC, GPR119 | RAB9A 2503/4885MAPT 2945/4885CASP3 1157/4885 |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | RAB9A 2407/4885MAPT 2022/4885CASP3 291/4885 |
| US-20240166611-A1 | TRIAZOLE DERIVATIVE AND USE THEREOF | FABP4, LIPC, GPR119 | RAB9A 2503/4885MAPT 2945/4885CASP3 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.